46.28
+0.17%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About PharmaBlock Sciences Nanjing
Its shares trade on Shenzhen under the ticker 300725.SZ. It has been listed since 10 November 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.97bn and net income of CN¥183.7m. At that date it held total assets of CN¥7.34bn and shareholders' equity of CN¥6.30bn.
PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Nov 2017
- Employees
- 2,487
- Website
- pharmablock.com ↗
Leadership
Pay as last reported
- Mr. Minmin YangChairman of the Board, General Manager, since 2008CN¥711,500
- Ms. Juanjuan WuFinance Director, Director, since 2018CN¥443,800
- Mr. Zhihong ChenExecutive Deputy General Manager
- Mr. Shanbao YuSecretary of the Board, since 2021CN¥747,600
- Ms. Chen ChenDirector
- Ms. Yuanping JieDirector, since 2016CN¥726,300
- Mr. Xihe JiangIndependent Director
- Mr. Li JinIndependent DirectorCN¥6,700
- Ms. Xiaonan ZhengIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- PharmaBlock Sciences Nanjing Inc employs 2,487 full-time employees in Nanjing, China.
- The company specializes in aromatic heterocyclic drug molecular building blocks for pharmaceutical R&D.
- PharmaBlock Sciences offers four-membered ring drug molecular building blocks as key products.
Weaknesses
- The company's primary focus on Nanjing, Jiangsu limits its global market reach.
- PharmaBlock Sciences relies on a narrow product range of molecular building blocks.
- The firm's IPO in 2017 may indicate limited recent capital investment.
Opportunities
- Expanding into the Chinese pharmaceutical market could leverage PharmaBlock's Nanjing base.
- Growing demand for pharmaceutical intermediates presents a significant opportunity.
- The company can develop new saturated ring drug molecular building blocks for emerging markets.
Threats
- Competition from other Chinese pharmaceutical firms poses a risk to PharmaBlock's market share.
- Regulatory changes in China's pharmaceutical sector could impact operations.
- PharmaBlock's reliance on a single city for production may increase vulnerability to local disruptions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.